AbCellera Biologics Inc. [NASDAQ: ABCL] gained 5.40% on the last trading session, reaching $8.39 price per share at the time. The company report on May 10, 2022 that AbCellera Reports Q1 2022 Business Results.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Total revenue of $317 million, compared to $203 million in Q1 2021.
Six program starts in the quarter bringing cumulative total to 84, up 56% from Q1 2021.
AbCellera Biologics Inc. represents 283.89 million in outstanding shares, while the company has a total market value of $2.44 billion with the latest information. ABCL stock price has been found in the range of $8.39 to $9.10.
If compared to the average trading volume of 1.78M shares, ABCL reached a trading volume of 6183939 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about AbCellera Biologics Inc. [ABCL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for ABCL shares is $30.00 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on ABCL stock is a recommendation set at 1.70. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
The Benchmark Company have made an estimate for AbCellera Biologics Inc. shares, keeping their opinion on the stock as Buy, with their previous recommendation back on December 21, 2021. While these analysts kept the previous recommendation, Piper Sandler raised their target price to Overweight. The new note on the price target was released on November 19, 2021, representing the official price target for AbCellera Biologics Inc. stock. Previously, the target price had yet another raise to $45, while SVB Leerink analysts kept a Outperform rating on ABCL stock.
The Average True Range (ATR) for AbCellera Biologics Inc. is set at 0.62, with the Price to Sales ratio for ABCL stock in the period of the last 12 months amounting to 5.00. The Price to Book ratio for the last quarter was 1.97, with the Price to Cash per share for the same quarter was set at 1.87. Price to Free Cash Flow for ABCL in the course of the last twelve months was 14.72.
Trading performance analysis for ABCL stock
AbCellera Biologics Inc. [ABCL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.68. With this latest performance, ABCL shares gained by 26.36% in over the last four-week period, additionally sinking by -44.51% over the last 6 months – not to mention a drop of -66.22% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ABCL stock in for the last two-week period is set at 57.83, with the RSI for the last a single of trading hit 64.61, and the three-weeks RSI is set at 53.98 for AbCellera Biologics Inc. [ABCL]. The present Moving Average for the last 50 days of trading for this stock 8.16, while it was recorded at 7.88 for the last single week of trading, and 12.20 for the last 200 days.
AbCellera Biologics Inc. [ABCL]: A deeper dive into fundamental analysis
AbCellera Biologics Inc.’s liquidity data is similarly interesting compelling, with a Current Ratio set at 5.50.
AbCellera Biologics Inc. [ABCL]: An earnings per share (EPS) analysis
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for ABCL. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for AbCellera Biologics Inc. go to 10.00%.
An analysis of insider ownership at AbCellera Biologics Inc. [ABCL]
There are presently around $900 million, or 40.30% of ABCL stock, in the hands of institutional investors. The top three institutional holders of ABCL stocks are: CAPITAL WORLD INVESTORS with ownership of 18,267,775, which is approximately -17.159% of the company’s market cap and around 20.30% of the total institutional ownership; ALLIANZ ASSET MANAGEMENT GMBH, holding 11,158,045 shares of the stock with an approximate value of $88.82 million in ABCL stocks shares; and BAILLIE GIFFORD & CO, currently with $87.95 million in ABCL stock with ownership of nearly 209.151% of the company’s market capitalization.
Positions in AbCellera Biologics Inc. stocks held by institutional investors increased at the end of May and at the time of the May reporting period, where 69 institutional holders increased their position in AbCellera Biologics Inc. [NASDAQ:ABCL] by around 24,657,714 shares. Additionally, 57 investors decreased positions by around 16,713,335 shares, while 22 investors held positions by with 71,692,632 shares. The mentioned changes placed institutional holdings at 113,063,681 shares, according to the latest SEC report filing. ABCL stock had 30 new institutional investments in for a total of 9,350,535 shares, while 22 institutional investors sold positions of 2,521,440 shares during the same period.